Autolus Therapeutics (NASDAQ: AUTL) — Company Overview, News & Financial Data
Autolus Therapeutics develops next-generation T cell therapies for cancer treatment, aiming to improve clinical outcomes for patients.
Autolus Therapeutics
Autolus Therapeutics (NASDAQ:AUTL) is a biopharmaceutical company focused on the development and commercialization of next-generation programmed T cell therapies for the treatment of cancer. The company's pioneering work in CAR T cell therapy, aimed at harnessing the power of patients' immune systems to combat cancer, positions it at the forefront of cell and gene therapy. Autolus Therapeutics is committed to advancing a diverse portfolio of treatment candidates, with a primary objective of delivering life-changing benefits to patients facing serious diseases. Through innovative research and strategic partnerships, the company aims to improve clinical outcomes and fundamentally alter the cancer treatment landscape.
Snapshot
Operations
Products and/or services of Autolus Therapeutics
- Obe-cel (AUTO1): A CAR T-cell therapy aimed at treating adult acute lymphoblastic leukemia with a focus on reducing toxicity.
- AUTO1/22: A dual-targeting CAR T-cell therapy designed for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- AUTO3: A dual-targeting CAR T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia, emphasizing safety and efficacy.
- AUTO4: A T-cell receptor (TCR) therapy targeting TRBC1 for patients with T cell lymphomas, exploring a novel approach in cancer treatment.
- AUTO6: A CAR T-cell therapy focused on the treatment of solid tumors, aiming to expand the applicability of CAR T technology beyond hematological malignancies.
Autolus Therapeutics executive team
- Christian Martin ItinCEO & Director
- Martin PuleFounder, Senior VP & Chief Scientific Officer
- Robert F. DolskiSenior VP & CFO
- Christopher VannSenior VP & COO
- Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer
- Miranda NevilleSenior VP & Chief Technology Officer
- Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary
- Alexander SwanSenior VP & Chief Human Resources Officer
- Christopher WilliamsSenior VP & Chief Business Development Officer
- Matthias WillSenior VP & Chief Development Officer
Latest news about Autolus Therapeutics
Key financials
Reported results for Autolus Therapeutics, in USD.
- Market cap
- 376.6M
- Revenue (TTM)
- 117.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- -238.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 75.6M | -281.4M | -288.2M | |
| 10.1M | -241.4M | -220.7M | |
| 1.7M | -179.7M | -208.4M | |
| 6.2M | -142.9M | -148.8M |